Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023

ANN ARBOR, Mich.--()--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced the acceptance of a clinical abstract titled “Thermoacoustic assessment of fatty liver disease - a clinical feasibility study” for presentation at the Steatotic Liver Disease Summit 2023 hosted by the European Association for the Study of the Liver (EASL), taking place September 21-23 in Prague, Czechoslovakia.

“This poster presentation is focused on a comparison of TAEUS estimates of liver fat fraction to the established clinical gold standard of Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). We are delighted that ENDRA's clinical abstract was accepted by EASL for its annual summit focused on steatotic liver disease, which is the target of ENDRA's first TAEUS application. The study data add to ENDRA's growing clinical evidence and illustrate TAEUS' potential to assess fatty liver disease, non-invasively, at the point of care, in populations that include large subjects, and those with NASH or fibrosis,” stated Michael Thornton, Chief Technology Officer of ENDRA. “The data that will be presented include subjects that range from healthy to morbidly obese individuals, and those with confirmed liver fibrosis.”

Abstract Number: PO7-05
Title: Thermoacoustic assessment of fatty liver disease - a clinical feasibility study
Presenter: Michael Thornton
Session: 7
Date: September 23, 2023
Time: 11:00 am to 11:30 am Central European Time

The poster will be available on the Research and Media section of ENDRA's website after the conference ends.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with over 500,000 ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Steatotic Liver Disease (SLD) (formerly known as NAFLD-NASH), a chronic liver spectrum that affects over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

Forward-Looking Statements

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” "anticipate," “attempt,” "believe," "could," "estimate," "expect," “forecast,” “future,” "goal," “hope,” "intend," "may," "plan," “possible,” “potential,” “project,” "seek," "should," "will," “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: estimates of the timing of future events and anticipated results of our development efforts, including the timing for receipt of required regulatory approvals and product launches; future financial position and projected costs and revenue; expectations concerning ENDRA's business strategy; ENDRA’s ability to find and maintain development partners; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; and ENDRA’s ability to protect its intellectual property. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; the impact of COVID-19 on ENDRA’s business plans; the ability to find and maintain development partners; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; ENDRA’s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

Contacts

Irina Pestrikova
Senior Director, Finance
investors@endrainc.com
www.endrainc.com

Investor Relations:
Yvonne Briggs
LHA Investor Relations
(310) 691-7100
YBriggs@lhai.com

#Hashtags

$Cashtags

Social Media Profiles

Contacts

Irina Pestrikova
Senior Director, Finance
investors@endrainc.com
www.endrainc.com

Investor Relations:
Yvonne Briggs
LHA Investor Relations
(310) 691-7100
YBriggs@lhai.com